Together, both companies can offer end-to-end discovery solutions in the space of antibody drug conjugates (ADC) and other functional antibodies. Both companies are united by shared values of integrity, clear communication, and a passion for science.
Isogenica’s core expertise focuses on small-format VHH single-domain antibodies, sometimes known as ‘nanobodies’. Isogenica offers rapid antibody discovery services exploiting the world’s biggest VHH libraries. Projects are custom-tailored and include a broad spectrum of antibody engineering and characterisation services.
Axxam provides a consolidated expertise across a broad range of discovery platforms for the identification of small molecule compounds for different industrial applications. Axxam offers the access to a discovery library of 450,000 compounds composed of specific subsets, including natural compounds, provides key services including assay development, high-throughput screening and hit-to-lead optimization also as fully integrated discovery solutions from assay development to lead candidate through Axxam’s DiscoveryMAXX application.
“We are delighted to enter this collaboration with Axxam” said Bill Eldridge, CEO of Isogenica. “This partnership signifies an important moment for Isogenica to drive innovation and make a lasting impact on global healthcare clients who now have the opportunity to access Axxam’s high quality solutions and functional assays in the early phases of drug discovery with the aim of generating new valuable leads”.
“Axxam is excited to kick-off this strategic partnership with Isogenica. We are confident this collaboration will create new opportunities to accelerate the discovery of innovative therapeutic solutions. Together, we will unlock greater potential for our clients to bring novel treatments to patients,” said Stefan Lohmer, CEO of Axxam.
“Joining forces between Isogenica and Axxam in the form of a strategic partnership unlock new solutions for our customers and unravel new possibilities for both companies. Isogenica benefitting from the biology powerhouse that is Axxam and Axxam benefitting from the innovative VHH platform developed by Isogenica therefore stepping into a new discovery modality” added Ciriaco Maraschiello, COO of Axxam.
